Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032093 | 0.90 | TSHR (0.40) | CHRM1ALDH1A1TP53TDP1POLB | |
| SCHEMBL22032116 | 0.84 | CHRM1 (0.40) | CHRM1ALDH1A1MAPK1TP53TDP1 | |
| SCHEMBL22032121 | 0.84 | CHRM1 (0.40) | CHRM1ALDH1A1MAPK1TP53TDP1 | |
| SCHEMBL24106280 | 0.84 | CHRM1 (0.40) | CHRM1ALDH1A1MAPK1TP53TDP1 | |
| SCHEMBL22032105 | 0.83 | TP53 (0.39) | CHRM1ALDH1A1MAPK1TP53TDP1 | |
| SCHEMBL22032118 | 0.83 | — | — | |
| SCHEMBL22032103 | 0.82 | TP53 (0.32) | CHRM1TP53TDP1 | |
| SCHEMBL22032095 | 0.79 | TP53 (0.36) | CHRM1ALDH1A1TP53TDP1KDM4E | |
| SCHEMBL22032111 | 0.78 | CHRM1 (0.52) | CHRM1ALDH1A1MAPK1POLBKDM4E | |
| SCHEMBL22032089 | 0.78 | TP53 (0.32) | CHRM1ALDH1A1TP53TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | claimed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | claimed |
| EP-3891140-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | claimed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | claimed |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3891140-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ALDH1A1 1576/4885MAPK1 2288/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ALDH1A1 1576/4885MAPK1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.